mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

Article Immunology

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Jan-Stephan F. Sanders et al.

Summary: In kidney patients, the immunogenicity, tolerability, and safety of COVID-19 vaccination vary. Kidney transplant recipients have a poor immune response, while patients with CKD G4/5 and those on dialysis have a comparable response to the control group. Dialysis patients and transplant recipients experience fewer adverse events after vaccination.

TRANSPLANTATION (2022)

添加到收藏夹

Review Urology & Nephrology

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD

Edward J. Carr et al.

Summary: The effectiveness of SARS-CoV-2 vaccination in CKD patients, particularly transplant recipients and those receiving dialysis, varies in terms of antibody development rates. Further research is needed to evaluate the vaccine efficacy in these populations. Rigorous surveillance is crucial for early detection of potential adverse effects, especially for patients with autoimmune diseases and transplant recipients.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Biochemical Research Methods

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

Joachim Marien et al.

Summary: Large-scale serosurveillance of SARS-CoV-2 requires reliable, rapid, and affordable serological tests. Bead-based assays are a cost-effective alternative, with the combination of NP and RBD antigens showing high specificity for IgG detection. Severe cases typically exhibit clear IgM and IgA responses, while some mild cases may not reach detection thresholds in bead-based assays.

JOURNAL OF VIROLOGICAL METHODS (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Immunology

Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study-The COViNEPH Project

Alicja Debska-Slizien et al.

Summary: The humoral response to SARS-CoV-2 vaccination among kidney transplant recipients is low, with older age, shorter transplantation time, and use of more than two immunosuppressive drugs being independent predictors of a low response.

VACCINES (2021)

添加到收藏夹

Article Transplantation

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Benedikt Simon et al.

Summary: HD patients had significantly lower anti-SARS-CoV-2 S antibody titres compared to controls 21 days after vaccination. The HD group experienced fewer adverse events than the control group. There was no correlation between the antibody response to Hepatitis B vaccination and the SARS-CoV-2 vaccine.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Letter Rheumatology

Correspondence on SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response by Bonelli et al

Caoilfhionn Marie Connolly et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Urology & Nephrology

Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

Dominique Bertrand et al.

Summary: Immunization with BNT162b2 appears to be more effective in HDPs, with the immune response in KTRs potentially influenced by immunosuppressive medications. Current vaccinal strategies for KTRs may not provide adequate protection against COVID-19 and may need further improvement.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Letter Urology & Nephrology

Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients

Robert A. Kaiser et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Letter Oncology

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A. Ollila et al.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Julian Stumpf et al.

Summary: The study showed that dialysis patients had a high seroconversion rate after receiving the boost vaccination, while the majority of transplant recipients had impaired humoral responses. The type and number of immunosuppressive drugs, as well as the type of vaccine, were major determinants of seroconversion failure in both dialysis and transplant patients.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project

Karolina Polewska et al.

Summary: This study evaluated the safety and tolerances of vaccinating dialyzed patients with the BNT162b2 COVID-19 mRNA vaccine, and found that the vaccine was safe and well-tolerated in this patient group with lower reaction rates compared to the control group.

MEDICINA-LITHUANIA (2021)

添加到收藏夹

mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

相关参考文献

导出引文

分享论文